Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
This clinical trial is for men and women with newly diagnosed with acute Graft vs Host Disease (GvHD).
The purpose of this study is to evaluate if CYP-001 can be effective to treat GvHD that has not responded to steroids.
The study drug used in this study (CYP-001) is experimental. This means that it is not an approved treatment for high-risk acute GvHD by the U.S. Food and Drug Administration (FDA) or anywhere in the world.
Participants will be randomized to receive either CYP-001 IV infusion or placebo. Randomization is like flipping a coin and there is a 50/50 chance of being assigned to either group.
Participation is expected to last about 24 months.
Detailed eligibility will be reviewed when you contact the study team.